Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

56.93
+0.08000.14%
Post-market: 56.930.00000.00%19:30 EDT
Volume:1.72M
Turnover:97.82M
Market Cap:5.37B
PE:-119.49
High:57.53
Open:57.21
Low:56.34
Close:56.85
52wk High:68.73
52wk Low:22.59
Shares:94.26M
Float Shares:92.77M
Volume Ratio:1.08
T/O Rate:1.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:218.84
PE(LYR):-198.81

Loading ...

Travere Therapeutics Q2 Product Sales Rise on Filspari Demand

Reuters
·
Aug 05

Travere Q2 FY26 Net Loss Widens to $34.8 Million; Filspari Net Sales Rise 96% Year-over-Year to $141.1 Million

Reuters
·
Aug 05

Travere Therapeutics Q2 EPS USD -0.37

THOMSON REUTERS
·
Aug 05

Travere Therapeutics to Report Q2 Financial Results After US Market Close

Reuters
·
Jul 29

Travere Therapeutics (TVTX) Gets a Buy from Guggenheim

TIPRANKS
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), McKesson (MCK) and TG Therapeutics (TGTX)

TIPRANKS
·
Jul 22

Exploring High Growth Tech Stocks In The US For July 2026

Simply Wall St.
·
Jul 20

Analysts Offer Insights on Healthcare Companies: Pediatrix Medical Group (MD) and Travere Therapeutics (TVTX)

TIPRANKS
·
Jul 13

Travere Therapeutics Grants Inducement Equity Awards for 41,600 Shares to Six New Employees

Reuters
·
Jul 11

Travere Therapeutics CAO Sandra Calvin to Retire; Controller John Torell Set to Succeed

Reuters
·
Jul 10

US FDA Approves Vera's Kidney Disease Drug

Reuters
·
Jul 08

Everest Medicines Closes Exclusive Licensing, Collaboration Deal with Travere for Us$112.5 Million Upfront

Reuters
·
Jul 07

Travere Therapeutics (TVTX) Could Be 3% Undervalued As Russell Value Exits Stir Questions

Simply Wall St.
·
Jul 06

Travere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says

MT Newswires Live
·
Jun 22

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

InvestorPlace
·
Jun 19

Travere Therapeutics Names Inrig Incoming Research Chief, Succeeding Rote

Dow Jones
·
Jun 17

Travere Therapeutics director Roy D. Baynes disposes of common shares worth $225,000

Reuters
·
Jun 17

Travere Therapeutics announces retirement of Chief Research Officer in 2027

TIPRANKS
·
Jun 17

BRIEF-Travere Therapeutics Announces Planned Retirement Of Chief Research Officer In 2027

Reuters
·
Jun 17

Travere Therapeutics names Jula Inrig EVP, head of R&D, as CRO William Rote plans 2027 retirement

Reuters
·
Jun 17